Clinical Trial Update: A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib as monotherapy or intermittent dosing with docetaxel in advanced or metastatic non-small cell lung cancer; the study is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-11-16